M Pharmaceuticals Commences Trading on the Canadian Securities Exchange - Video News Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - January 29, 2015) - M Pharmaceuticals (CSE: MQ) is one of the latest new listings on the Canadian Securities Exchange. The company has signed an arms-length agreement to acquire and commercialize the rights to a biomedical device for the self-monitoring of blood glucose.

InvestmentPitch.com has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "M Pharma" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_gik6iyw7/M-Pharmaceuticals-CSE-MQ-New-Listing

This device, called the eMosquito, is designed to be a minimally-invasive skin penetration device to be used by diabetics. The objective of the eMosquito is to obtain whole blood samples by penetrating the skin to shallower depths and in less sensitive areas of the body.

Persons with diabetes have traditionally used the "finger prick" method to monitor/test their blood glucose levels, obtaining the blood sample by pricking the finger tip, a highly sensitive area of the body. The eMosquito is envisioned to be worn like a patch with small needles designed to puncture the skin just deep enough to draw blood without affecting the nerve endings and causing little or no pain.

The idea behind the technology is to have an integrated cuff-based device which automatically draws whole blood samples and monitors blood glucose levels on a regular basis. Integrated on a wrist-wear cuff, the Electronic Mosquito is composed of at least six single-use needles that "bite" sequentially at preprogrammed intervals.

A novel shape memory alloy based actuation mechanism will provide the driving force. Following that, a commercial strip-based sensor associated with each needle will measure glucose level in the blood sample withdrawn from the bite. Then, this data will be sent wirelessly to a remote device such as a smartphone for further data analysis, interpretation or even guiding the dosing decisions of an artificial pancreas. The patient merely has to replace the needles and the strips once per day.

The company is trading at $0.025 and with 80.7 million shares outstanding, is capitalized at $2 million.

For more information, please visit the company's website www.m-pharma.ca, contact Zachary T. Stadnyk at 604-428-0511 or email zach@m-pharma.ca.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com